Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yves-Line Delva
Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy
PLoS ONE
Multidisciplinary
Related publications
Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Advances in Therapy
Medicine
Pharmacology
In Vitro Cellular Drug Resistance in Children With Relapsed/Refractory Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Treatment Outcome in Infant Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Outcome of Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia After Blinatumomab Failure: No Change in the Level of CD19 Expression
American Journal of Hematology
Hematology
Pcn142 - Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn71 - Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Correlates of Resistance and Relapse During Blinatumomab Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
American Journal of Hematology
Hematology
